The estimated Net Worth of Denise M Morrison is at least 6.6 百万$ dollars as of 6 August 2019. Ms. Morrison owns over 1,000 units of Quest Diagnostics stock worth over 494,924$ and over the last 21 years she sold DGX stock worth over 5,798,753$. In addition, she makes 308,654$ as Independent Director at Quest Diagnostics.
Sign up
Ms. Morrison DGX stock SEC Form 4 insiders trading
Denise has made over 7 trades of the Quest Diagnostics stock since 2005, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of DGX stock worth 171,130$ on 6 August 2019.
The largest trade she's ever made was exercising 127,000 units of Quest Diagnostics stock on 5 September 2012 worth over 3,100,070$. On average, Denise trades about 2,535 units every 47 days since 2003. As of 6 August 2019 she still owns at least 3,223 units of Quest Diagnostics stock.
You can see the complete history of Ms. Morrison stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Denise Morrison biography
Denise M. Morrison serves as Independent Director of the Company. Ms. Morrison is the founder of Denise Morrison & Associates, LLC, a consulting firm. She retired in 2018 as the President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of Visa, Inc. and MetLife, Inc., and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, the Advisory Counsel for Just Capital, and the Advisory Board for Tufts Friedman School of Nutrition Science and Policy and is a member of The Business Council. Ms. Morrison served on President Trump’s Manufacturing Jobs Initiative as well as President Obama’s Export Council.
What is the salary of Denise Morrison?
As the Independent Director of Quest Diagnostics, the total compensation of Denise Morrison at Quest Diagnostics is 308,654$. There are 12 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of 10,118,500$.
How old is Denise Morrison?
Denise Morrison is 66, she's been the Independent Director of Quest Diagnostics since 2019. There are 3 older and 18 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
What's Denise Morrison's mailing address?
Denise's mailing address filed with the SEC is METLIFE, INC., 200 PARK AVENUE, NEW YORK, NY, 10166.
Insiders trading at Quest Diagnostics
Over the last 21 years, insiders at Quest Diagnostics have traded over 67,426,608$ worth of Quest Diagnostics stock and bought 34,000 units worth 1,910,090$ . The most active insiders traders include Plc Gsk、James F Iii Flaherty、Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of 3,750,703$. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth 3,118,386$.
What does Quest Diagnostics do?
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
What does Quest Diagnostics's logo look like?
Complete history of Ms. Morrison stock trades at Goodyear Tire & Rubber Co、Campbell Soup Co、Metlife Inc、Quest Diagnostics、Visa Inc
Quest Diagnostics executives and stock owners
Quest Diagnostics executives and other stock owners filed with the SEC include:
-
Stephen Rusckowski,
Chairman of the Board, President, Chief Executive Officer -
Manuel Mendez,
Executive Officer -
Stephen H. Rusckowski,
Chairman, Pres & CEO -
Mark Guinan,
Chief Financial Officer, Executive Vice President -
James Davis,
Executive Vice President, General Diagnostics -
Carrie Manner,
Senior Vice President - Advanced Diagnostics -
Catherine Doherty,
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing -
Michael Prevoznik,
Senior Vice President, General Counsel -
James E. Davis,
Exec. VP of Gen. Diagnostics -
Carrie Eglinton Manner,
Sr. VP of Advanced Diagnostics -
Daniel Stanzione,
Lead Independent Director -
Gary Pfeiffer,
Independent Director -
Denise Morrison,
Independent Director -
Gail Wilensky,
Independent Director -
Timothy Main,
Independent Director -
Timothy Ring,
Independent Director -
Vicky Gregg,
Independent Director -
Helen Torley,
Independent Director -
Wright Lassiter,
Independent Director -
Michael E. Prevoznik,
Sr. VP & Gen. Counsel -
Mark J. Guinan,
Exec. VP & CFO -
Gary D. Samuels,
VP of Corp. Communications -
Timothy Sharpe,
VP of Compliance -
Shawn C. Bevec,
VP of Investor Relation -
Gabrielle Wolfson,
Sr. VP and Chief Information & Digital Officer -
Michael J. Deppe,
VP, Corp. Controller & Chief Accounting Officer -
Robert B Carter,
Director -
Jeffrey M Leiden,
Director -
Jenne K Britell,
Director -
Robert A Klug,
VP, Corporate Controller -
Everett Cunningham,
SVP, Commercial -
John B Ziegler,
Director -
Jon R Cohen,
SVP and Chief Medical Officer -
William F Buehler,
Director -
John B. Haydon,
SVP, Operations -
Kathy Ordonez,
SVP, Discovery & Development -
Robert Hagemann,
Corp VP & Chief Fin Officer -
Surya N Mohapatra,
President & COO -
Joan Elizabeth Miller,
Sr VP -Pathology& HospServices -
John C Md Baldwin,
Director -
Wayne R. Simmons,
Vice President, Operations -
Rosanne Haggerty,
Director -
Plc Gsk,
10% owner -
Thomas W Ii Grant,
Executive Officers -
William R Grant,
Director -
Thomas F Bongiorno,
Vice President and Controller -
James F Iii Flaherty,
Director -
David M Zewe,
Sr. VP -Diagnostic Testg Ops -
Robert E Peters,
Vice President, Sales & Mktg. -
Kenneth W/Nj Freeman,
Chairman, Chief Exec Officer -
Mary A Cirillo,
Director -
Kenneth D Brody,
Director -
Gerald C Marrone,
Sr. VP, Administration -
Luis Diaz,
Director -
Tracey Doi,
Director -
Michael J Deppe,
SVP, Corp. Controller & CAO -
Sam Samad,
Executive Vice President & CFO -
Patrick Plewman,
SVP for Diagnostic Services -
Karthik Kuppusamy,
SVP, Clinical Solutions -
J. E. Davis,
CEO and President -
Mark E Delaney,
SVP & Chief Commercial Officer -
Mark A Gardner,
SVP of Molecular Gen & Oncol